Biotron Limited (AU:BIT) has released an update.
Biotron Limited has announced positive outcomes from its Phase 2 HIV-1 clinical trial with its lead drug BIT225 achieving all primary objectives, including safety and potential immune-modulating effects. The Company is also progressing well in post-clinical activities for their COVID-19 trial and advancing its Hepatitis B program, underscoring its commitment to addressing unmet medical needs with its novel antiviral platform.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
